About Us

Dr. Jan Marie-Albert Van Tornout, MA MD MSc. (Founder & Global Strategic Consultant) is an accomplished physician-scientist with over 30 years of expertise in clinical development and medical affairs, specializing in hematological, oncological, and immuno-oncological diseases. His career has spanned both academic and industry roles, with significant contributions to the development of innovative therapies across the full spectrum of cancer treatment.

Dr. Van Tornout has a strong foundation in clinical research, leading programs from preclinical candidate selection through pre-IND, IND, POC, and pivotal Phase I–III trials, as well as overseeing NDA and BLA submissions. His leadership in hematology and oncology drug development has included the successful co-development of assets such as small & large molecules, monoclonal antibodies, biologics, and immune modulators. Dr. Van Tornout has driven the regulatory approval of multiple therapies in areas including multiple myeloma, leukemia, and solid tumors like non-small cell lung cancer and breast cancer.

Throughout his career, Dr. Van Tornout has held senior executive roles, including Chief Medical Officer at Elevar Therapeutics and TYME Technologies, and has provided strategic consultancy for various companies including Revelar Biotherapeutics, Moleculin Biotech and GSK. His contributions have extended to managing clinical development, regulatory affairs, and cross-functional teams globally, ensuring the timely and effective progression of clinical assets from bench to market.

Dr. Van Tornout holds a medical degree from the Katholieke Universiteit Leuven, where he also completed his pediatric residency. He completed his pediatric hematology/oncology fellowship at Childrens Hospital Los Angeles and earned a Master’s in Applied Biometry and completed post-doctoral studies in molecular epidemiology at the University of Southern California (USC). His academic contributions include serving as an Assistant Professor at USC, where his research focused on cancer pharmacogenomics and gene-environment interactions.

Dr. Van Tornout’s authored several peer reviewed publications and his work is distinguished by his deep expertise in clinical drug devekopment and clinical safety, regulatory interactions with agencies such as the FDA and EMA, and his ability to lead large, multidisciplinary teams. His passion for science and commitment to advancing cancer treatment continues to drive his consultancy work, where he advises biotech companies on strategic development, clinical trial design, and regulatory pathways.